Document Detail


Beneficial effects of the combination of nifedipine and losartan in hypertensive Dahl salt-sensitive rats.
MedLine Citation:
PMID:  17666919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The antihypertensive and organ-protective effects of the combination of the angiotensin II type 1 receptor blocker losartan and the calcium channel blocker nifedipine were examined in Dahl salt-sensitive rats. METHODS: The rats fed with a high-salt diet developed hypertension accompanied by aorta and heart hypertrophy, and impaired renal function. The animals were treated with losartan (30 mg/kg/day), nifedipine (7.8 mg/kg/day) or with a combination of both drugs for 8 weeks. At the end of the study systolic blood pressure, kidney function, organ weight, and mRNA expression were investigated. RESULTS: Losartan reduced significantly the systolic blood pressure as well as the aorta and left ventricular hypertrophy. Nifedipine and its combination with losartan had similar effects on the systolic blood pressure, aorta and left ventricular hypertrophy but only the combination treatment reduced the expression of transforming growth factor-beta1 in aorta and brain natriuretic peptide in left ventricle significantly. Nifedipine and the combination therapy reduced proteinuria and improved urine creatinine excretion. The expression of collagen III and IV in the kidney was significantly reduced by the combination therapy. CONCLUSION: These results indicate that although losartan and nifedipine were effective in lowering blood pressure and showed moderate organ protection, additional benefits can be expected by combination therapy with both compounds.
Authors:
Hanna Tinel
Related Documents :
2830189 - Individual responses to converting enzyme inhibitors and calcium antagonists.
17227609 - Preliminary evaluation of the use of a cdma-based emergency telemedicine system.
1698129 - Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose pota...
12395979 - Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continu...
2912599 - Effects of calcium channel antagonists on carotid sinus baroreflex control of arterial ...
10737129 - Is there any difference between intermediate-acting and long-acting calcium antagonists...
21978219 - Radial pressure pulse and heart rate variability in normotensive and hypertensive subje...
17198909 - The g-231a polymorphism in the endothelin-a receptor gene is associated with lower aort...
16215389 - Effect of increased cardiac output on hepatic and intestinal microcirculatory blood flo...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  50     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-08-01     Completed Date:  2007-12-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  75-82     Citation Subset:  IM    
Affiliation:
Product Related Research, Pharmacology, Pharma R&D Discovery Research, Bayer HealthCare AG, Wuppertal, Germany. hanna.tinel@bayerhealthcare.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / pharmacology*
Animals
Aorta / metabolism
Blood Pressure / drug effects
Calcium Channel Blockers / pharmacology*
Drug Therapy, Combination
Gene Expression
Hypertension / chemically induced,  drug therapy*
Hypertrophy, Left Ventricular / complications,  drug therapy
Kidney / metabolism
Losartan / pharmacology*
Male
Natriuretic Peptide, Brain / metabolism
Nifedipine / pharmacology*
Organ Size
RNA, Messenger / metabolism
Rats
Rats, Inbred Dahl
Sodium Chloride, Dietary
Transforming Growth Factor beta1 / metabolism
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Calcium Channel Blockers; 0/RNA, Messenger; 0/Sodium Chloride, Dietary; 0/Transforming Growth Factor beta1; 114471-18-0/Natriuretic Peptide, Brain; 114798-26-4/Losartan; 21829-25-4/Nifedipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to t...
Next Document:  Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor depe...